Greenstone Biosciences
Greenstone Biosciences is a Palo Alto-based drug discovery platform that supplies human iPSC-derived cells, 3D organoids, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers, anchored by the world's largest human iPSC biobank of more than 2,500 individuals.
- Company typePrivate
- Founded2021
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Greenstone Biosciences does
Greenstone Biosciences is a private, Palo Alto-based drug discovery platform founded in 2021 that supplies human induced pluripotent stem cell (iPSC)-derived products, 3D organoid models, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers. The company's core asset is what it describes as the world's largest human iPSC biobank, generated from more than 2,500 individuals and including the largest collection of iPSCs derived from rare orphan disease patients. The product portfolio spans standardized cell products (iPSC lines, ventricular and atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells), 3D organoids (cardiac, pancreatic islet, gut, and vascularized variants), and contract research services including PBMC collection and reprogramming, custom differentiation, genetic engineering, high-throughput screening, clinical-trial-in-a-dish, CARTOX (hERG) cardiac safety, hepatotoxicity, gut barrier, and pancreatic islet functional assays. The platform is positioned around the FDA's New Approach Methodologies (NAMs) agenda, citing the FDA Modernization Act 2.0 (2022) and the 2025 phase-out of animal testing for monoclonal antibodies as demand catalysts.
The company's commercial model operates through three channels: a direct e-commerce storefront selling per-vial products at $200 (iPSCs) to $2,500–$3,100 (organoids) with academic pricing; quote-based custom services for enterprise and pharma clients; and longer-cycle drug discovery partnerships. Greenstone has signed high-profile technology integrations with Intel (Edge AI infrastructure, announced at Computex 2026), NVIDIA (AI drug toxicity models), and Illumina (genomics), alongside strategic co-development deals with Neolaia Bio (IBD), Cibus Therapeutics (chronic pancreatitis, CBT-101), and Creative Medical Technology (BioDefense Veterans Initiative). The ADMET-AI platform (admet.ai.greenstonebio.com) provides machine-learning-based absorption, distribution, metabolism, excretion, and toxicity prediction layered on top of the wet-lab biobank. The company is co-founded by Dr. Joseph C. Wu, Director of the Stanford Cardiovascular Institute, and is headquartered at Stanford Research Park, Palo Alto, California.
Greenstone Biosciences firmographics
Firmographics- Name
- Greenstone Biosciences
- Legal name
- Greenstone Biosciences, Inc.
- Website
- https://greenstonebio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Greenstone Biosciences is a Palo Alto-based drug discovery platform that supplies human iPSC-derived cells, 3D organoids, and AI-enabled preclinical services to pharmaceutical, biotechnology, and academic customers, anchored by the world's largest human iPSC biobank of more than 2,500 individuals.
- Ownership category
- akta.pro rank
Greenstone Biosciences industry classification
Industry- Product category
- Biotechnology Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Greenstone Biosciences is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Greenstone Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- iPSC and Cell Products: Sale of standardized human iPSC lines, differentiated cells (cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, epithelial cells), and organoid products for research and drug discovery applications
- Custom Services: Customized services including PBMC collection and iPSC reprogramming, genetically engineered iPSCs, clinical trial in a dish, CARTOX hERG toxicity assays, hepatotoxicity screens, and specialized disease modeling
- Drug Discovery Partnerships: Strategic collaborations with pharmaceutical and biotech companies for drug discovery programs using human iPSC models and AI platforms
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | iPSC - Academia product line |
| Unit Pricing | Pay-as-you-go | Differentiated cell products |
| Unit Pricing | Pay-as-you-go | Organoid products |
| Other | Multi-year contract | Custom services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Greenstone Biosciences product offering
Product offeringCore offering
Greenstone Biosciences operates a human induced pluripotent stem cell (iPSC) drug discovery platform anchored by what it claims is the world's largest human iPSC biobank of 2,500+ individuals, including the largest collection of rare orphan disease iPSCs. It sells standardized iPSC lines, differentiated cell types, and 3D organoids, and provides contract research services spanning iPSC reprogramming, genome editing, high-throughput screening, ADMET-AI predictive analytics, and cardiac/hepatic safety assays for pharmaceutical and academic clients.
Product overview
Greenstone Biosciences operates as a biotech company offering a comprehensive platform of human iPSC-based products and services for drug discovery. The core offering centers on the world's largest human iPSC biobank (2,500+ individuals), which powers two main product lines: hiPSC-derived cells (ventricular/atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells) and 3D organoids (cardiac, pancreatic, gut organoids with vascularized variants). The portfolio is complemented by a suite of contract research services including iPSC reprogramming, custom differentiation, high-throughput screening, and specialized toxicity assays (CARTOX/hERG, hepatotoxicity). The ADMET-AI platform adds AI-powered predictive analytics for absorption, distribution, metabolism, excretion, and toxicity evaluation. Together, these products and services enable human-centric drug discovery that reduces reliance on animal testing and aligns with FDA New Approach Methodologies (NAMs) guidance.
Differentiator
Problem solved
Functional benefit
Products and services
- ADMET-AI AI-powered platform for absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction using machine learning to accelerate drug candidate evaluation for pharmaceutical and biotech drug developers.
- hiPSC-Derived Cells Human induced pluripotent stem cell-derived cell types including ventricular cardiomyocytes, atrial cardiomyocytes, fibroblasts, smooth muscle cells, macrophages, endothelial cells, and intestinal epithelial cells for disease modeling and drug discovery, sold to academic and pharmaceutical researchers.
- Organoids 3D organ-like tissue models generated from iPSCs including ventricular cardiac organoids, atrial cardiac organoids, pancreatic islet organoids, gut organoids, vascularized ventricular cardiac organoids, and vascularized atrial cardiac organoids for disease modeling and drug discovery.
- PBMC Collection and iPSC Reprogramming Collection of peripheral blood mononuclear cells and reprogramming into induced pluripotent stem cells for research and therapeutic applications, provided as a custom service to research and biotech clients.
- Custom Differentiated iPSCs Custom differentiation services to generate specific cell types from iPSC lines for specialized research needs, delivered on a quote basis to academic and pharmaceutical clients.
- Genetically Engineered iPSCs Genome editing services (CRISPR/Cas9 and related) to create genetically modified iPSC lines with specific mutations or modifications for disease modeling, sold to research and drug discovery clients.
- High-Throughput Drug Discovery Scalable screening service using iPSC-derived cells and organoids for rapid drug candidate evaluation across multiple conditions, delivered to pharmaceutical and biotech clients.
- Cell Village Panel of diverse iPSC lines representing population-scale genetic diversity for comprehensive drug testing, offered as a custom service for population-level drug response studies.
- Clinical Trial in a Dish Personalized medicine service using patient-derived iPSCs to predict individual drug responses before clinical trials, delivered to pharmaceutical and biotech clients.
- CARTOX (hERG Toxicity Assay) Cardiac safety screening service assessing hERG potassium channel blockade to predict drug-induced heart rhythm abnormalities, delivered to pharmaceutical preclinical safety teams.
- Hepatotoxicity Screen Liver toxicity assessment service using human cellular models to predict drug-induced hepatotoxicity during drug development, sold to pharmaceutical preclinical safety teams.
- Functional Assays of Gut Barrier Integrity and Disease Modelling Intestinal barrier function assessment and disease modeling service using gut organoids for gastrointestinal drug development, delivered to research and pharmaceutical clients.
- Pancreatic Islet Organoid – Glucose Sensitivity Beta-cell function assessment service measuring glucose-stimulated insulin secretion responses in pancreatic islet organoids, delivered to diabetes and metabolic disease researchers.
Quantifiable outcome
- Up to 92% of drugs fail in human trials despite preclinical testing in animals
- +1 more outcomes
Companies that use Greenstone Biosciences
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Greenstone Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Greenstone Biosciences partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and strategic.
- Intel Corp.coreStrategic collaboration to scale human-centric drug discovery by integrating Greenstone's induced pluripotent stem cell biobank with Intel's Edge AI computing and infrastructure. The partnership aims to accelerate AI-enabled drug discovery, improve drug safety assessment, and advance precision medicine, highlighted during Intel's Computex 2026 keynote.
- Neolaia BiostrategicStrategic collaboration to advance inflammatory bowel disease (IBD) drug development using iPSC-derived macrophages and patient-relevant human gut organoid models. Neolaia provides proprietary drug candidates while Greenstone evaluates them using its human-based disease modeling platform.
- Cibus TherapeuticsstrategicPartnership with Mission: Cure and Greenstone Biosciences to advance CBT-101, a novel therapy for chronic pancreatitis. The collaboration combines drug development, stem cell AI-based discovery, and patient advocacy, aiming to begin clinical trials in 2026.
- Creative Medical Technology HoldingsstrategicPartnership for the BioDefense Veterans Initiative to address health issues caused by toxic burn pit exposure among U.S. veterans. Greenstone provides molecular and cellular data analysis systems to develop predictive models and treatments using AI-integrated regenerative biodefense.
- NVIDIAcoreCollaboration to develop AI models predicting drug toxicity using human cellular systems. The project aims to enhance drug safety testing, reduce reliance on animal testing, and advance precision therapeutics, aligning with FDA's strategic shift to new methodologies.
- IlluminacoreCollaboration to advance precision drug discovery by integrating Greenstone's iPSC biobank with Illumina's genomics technologies. The partnership aims to generate detailed molecular maps to enhance understanding of disease biology and accelerate drug development across multiple therapeutic areas.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Greenstone Biosciences competitors and assessment
Company assessmentDirect peers
- Insitro: Insitro combines iPSC-derived disease models with machine learning to drive drug discovery partnerships with pharma. It mirrors Greenstone's strategy of integrating iPSC biology, AI/ML, and pharma discovery collaborations, and overlaps on ADMET prediction and target ID workflows.
- Ncardia: Ncardia provides human iPSC-derived cell products and services, including iPSC-derived cardiomyocytes, used for cardiac safety and drug discovery. It directly competes with Greenstone's ventricular/atrial cardiomyocytes, CARTOX/hERG assays, and cardiovascular disease modeling offerings.
- BrainXell: BrainXell specializes in iPSC-derived neural cell types for CNS disease modeling and drug discovery. Like Greenstone, it serves academic researchers and pharma with custom differentiated iPSCs, overlapping with Greenstone's broader cell-type catalog and target identification services.
- Emulate Inc. Emulate offers organ-on-chip and micro-physiological systems used for human-relevant preclinical drug testing. Its organ-Chip platform competes directly with Greenstone's organoid systems for ADMET, hepatotoxicity, and gut barrier integrity services.
- Bit.bio: Bit.bio has developed an iPSC reprogramming and cell-coding platform that produces human cell types at scale for research and drug discovery. Its deterministic reprogramming approach competes directly with Greenstone's iPSC biobank, custom differentiated iPSCs, and Cell Village offerings.
- Cellular Dynamics (FUJIFILM): Cellular Dynamics International, now part of FUJIFILM, is the established leader in commercial iPSC-derived cell products including iCell cardiomyocytes. It is the incumbent against which Greenstone's $200 academic iPSC vials and differentiated cell products are differentiated.
- Axol Bioscience: Axol Bioscience manufactures iPSC-derived cell products including cardiomyocytes, neurons, and endothelial cells for disease modeling and drug discovery. Its iPSC-derived cell catalog, especially cardiac and neuronal lines, directly overlaps with Greenstone's hiPSC-Derived Cells and organoid product lines.
Broad incumbents
- CytoReason: CytoReason provides AI-driven multi-omics data analysis and disease models for pharma R&D, used to accelerate drug discovery and target identification. Its AI/omics platform overlaps with Greenstone's ADMET-AI and Bioinformatics/Multi-Omics positioning for enterprise pharma customers.
- Recursion Pharmaceuticals: Recursion is a publicly listed AI-driven drug discovery platform combining high-throughput biology with proprietary ML. Its larger scale and broader pipeline make it a broad incumbent against Greenstone's AI-drug-discovery ambitions, especially in partnership pitches to large pharma.
Emerging players
- Xilis: Xilis has built a micro-organoid platform for patient-derived drug screening and predictive oncology. While oncology-focused, its micro-organoid platform parallels Greenstone's 3D organoid drug-discovery offering and competes for pharma discovery service budgets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Greenstone Biosciences social profiles
Digital presenceGreenstone Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Greenstone Biosciences leadership team
Management profileNumber of profiles
Profiles2 records
Greenstone Biosciences funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Greenstone Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Greenstone Biosciences
What does Greenstone Biosciences do?
Greenstone Biosciences operates a human induced pluripotent stem cell (iPSC) drug discovery platform anchored by what it claims is the world's largest human iPSC biobank of 2,500+ individuals, including the largest collection of rare orphan disease iPSCs. It sells standardized iPSC lines, differentiated cell types, and 3D organoids, and provides contract research services spanning iPSC reprogramming, genome editing, high-throughput screening, ADMET-AI predictive analytics, and cardiac/hepatic safety assays for pharmaceutical and academic clients.
Is Greenstone Biosciences a public or private company?
Greenstone Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Greenstone Biosciences founded?
Greenstone Biosciences was founded in 2021. It employs 11 to 50 people.
Where is Greenstone Biosciences based?
Greenstone Biosciences is headquartered in Palo Alto, United States, in the North America region.
How does Greenstone Biosciences make money?
Three revenue lines are on record. iPSC and Cell Products are the primary driver. The others are custom Services and drug Discovery Partnerships.
Who are Greenstone Biosciences's main competitors?
Direct peers on record are Insitro, Ncardia, BrainXell, Emulate Inc., Bit.bio, Cellular Dynamics (FUJIFILM) and Axol Bioscience. Broad incumbents are CytoReason and Recursion Pharmaceuticals. Xilis is listed as an emerging player.
Does Greenstone Biosciences have an API?
No public API is recorded for Greenstone Biosciences.
What industry is Greenstone Biosciences in?
Greenstone Biosciences's product category is Biotechnology Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.